Third quarter 2026
Filed Nov 2, 2026Third-quarter revenue rose 10% as reported and organic, EPS increased 18% as reported, and IDEXX raised its 2026 revenue and EPS outlook.
IDEXX delivered $1,214,237 thousand of third-quarter revenue, 9.9% reported growth, with CAG Diagnostics recurring revenue up 10.8%, gross margin expanding 110 basis points, operating margin expanding 100 basis points, and diluted EPS increasing 18%. The company raised its full-year revenue and EPS outlook, although it lowered reported operating-margin guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $1.21B | – | 9.9% |
| Revenue, nine months ended September 30, 2026GAAP | $3.57B | – | 11.2% |
| Organic revenue growth, three months ended September 30, 2026non-GAAP | 10.0% | – | 10.0% |
| Organic revenue growth, nine months ended September 30, 2026non-GAAP | 10.0% | – | 10.0% |
| Gross profit, three months ended September 30, 2026GAAP | $764.3M | – | 12% |
| Gross margin, three months ended September 30, 2026GAAP | 62.9% | – | 110 bps |
| Comparable gross profit, three months ended September 30, 2026non-GAAP | $763.2M | – | 12% |
| Comparable gross margin, three months ended September 30, 2026non-GAAP | 62.7% | – | 90 bps |
| Gross profit, nine months ended September 30, 2026GAAP | $2.27B | – | 13% |
| Gross margin, nine months ended September 30, 2026GAAP | 63.4% | – | 120 bps |
| Operating expenses, three months ended September 30, 2026GAAP | $361.9M | – | 10% |
| Comparable operating expenses, three months ended September 30, 2026non-GAAP | $365.0M | – | 11% |
| Operating expenses, nine months ended September 30, 2026GAAP | $1.08B | – | 12% |
| Comparable operating expenses, nine months ended September 30, 2026non-GAAP | $1.07B | – | 10% |
| Income from operations, three months ended September 30, 2026GAAP | $402.3M | – | 13% |
| Operating margin, three months ended September 30, 2026GAAP | 33.1% | – | 100 bps |
| Comparable operating profit, three months ended September 30, 2026non-GAAP | $398.2M | – | 12% |
| Comparable operating margin, three months ended September 30, 2026non-GAAP | 32.7% | – | 60 bps |
| Income from operations, nine months ended September 30, 2026GAAP | $1.19B | – | 14% |
| Operating margin, nine months ended September 30, 2026GAAP | 33.3% | – | 80 bps |
| Comparable operating profit, nine months ended September 30, 2026non-GAAP | $1.17B | – | 13% |
| Comparable operating margin, nine months ended September 30, 2026non-GAAP | 33.1% | – | 90 bps |
| Net income attributable to stockholders, three months ended September 30, 2026GAAP | $317.1M | – | – |
| Net income attributable to stockholders, nine months ended September 30, 2026GAAP | $934.0M | – | – |
| Diluted earnings per share, three months ended September 30, 2026GAAP | $4.01 | – | 18% |
| Comparable diluted earnings per share, three months ended September 30, 2026non-GAAP | $3.96 | – | 22% |
| Basic earnings per share, three months ended September 30, 2026GAAP | $4.02 | – | – |
| Diluted earnings per share, nine months ended September 30, 2026GAAP | $11.75 | – | 18% |
| Comparable diluted earnings per share, nine months ended September 30, 2026non-GAAP | $11.32 | – | 18% |
| Basic earnings per share, nine months ended September 30, 2026GAAP | $11.80 | – | – |
| Free cash flow, three months ended September 30, 2026non-GAAP | $420.8M | – | – |
| Free cash flow, nine months ended September 30, 2026non-GAAP | $977.6M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| CAG, three months ended September 30, 2026Strong same-store volume growth, IDEXX innovation benefits, net customer gains and premium instrument installed base expansion. | $1.12B | – | 10.2% |
| CAG Diagnostics recurring revenue, three months ended September 30, 2026IDEXX VetLab consumables growth, reference laboratory diagnostic and consulting-services growth, and growth in CAG Diagnostics services and accessories. | $967.4M | – | 10.8% |
| Water, three months ended September 30, 2026Growth in North America. | $58.84M | – | 8.4% |
| LPD, three months ended September 30, 2026Growth in the Americas. | $34.83M | – | 2.6% |
| Other, three months ended September 30, 2026No driver provided. | $4.61M | – | 3.2% |
| CAG, nine months ended September 30, 2026No driver provided. | $3.29B | – | 11.3% |
| Water, nine months ended September 30, 2026No driver provided. | $167.7M | – | 11.3% |
| LPD, nine months ended September 30, 2026No driver provided. | $102.5M | – | 8.7% |
| Other, nine months ended September 30, 2026No driver provided. | $13.23M | – | (1.2)% |
Full year 2026 outlook
- Revenue$4,741 - $4,767 million; reported growth of 10.1% - 10.8%; organic growth of 9.3% - 10.0%
- Tax rateEffective tax rate of ~20.5%; share-based compensation tax rate benefit of ~1.3%
- NoteCAG Diagnostics recurring revenue reported growth of 11.0% - 11.7% and organic growth of 10.3% - 11.0%.
- NoteOperating Margin of 32.1% - 32.3%.
- NoteOperating margin expansion of 50 bps - 70 bps.
- NoteComparable margin expansion of 50 bps - 70 bps.
- NoteEPS of $14.96 - $15.16; reported growth of 14% - 16%; comparable growth of 15% - 16%.
- NoteNet interest expense of ~$32.
- NoteShare-based compensation tax benefit of ~$19.
- NoteShare-based compensation EPS impact of ~$0.24.
- NoteReduction in average shares outstanding of ~2%.
- NoteOperating Cash Flow (% of Net Income) of 110% - 120%.
- NoteFree Cash Flow (% of Net Income) of 95% - 100%.
- NoteCapital Expenditures of ~$160.
- NoteEstimated foreign currency exchange-rate impact on 2026 revenue growth rate of ~0.7%, CAG Diagnostics recurring revenue growth rate of ~0.7%, operating margin growth of ~30 bps, EPS of ~$0.25, and EPS growth of ~2%.
Capital returns
- Three-month open-market repurchases: 199 shares at a cost of $111,819 thousand; average cost per share of $563.04.
- Nine-month open-market repurchases: 1,369 shares at a cost of $804,698 thousand; average cost per share of $588.14.
- Nine-month total cost of shares repurchased: $815,701 thousand.
- Nine-month repurchases of common stock in the condensed consolidated statement of cash flows: $810,014 thousand.
What drove it
- CAG Diagnostics recurring revenue grew 11% as reported and organic, including 13% reported and 14% organic growth in International regions and 10% reported and organic growth in the U.S.
- IDEXX VetLab consumables revenue grew 14% reported and 15% organic, supported by net new customer growth, 11% expansion of the IDEXX global premium instrument installed base, utilization expansion, and net price gains.
- Reference laboratory diagnostic and consulting-services revenue grew 10% reported and organic, driven by testing volume growth, net new customer gains, and price realization.
- IDEXX placed over 1,900 IDEXX inVue Dx analyzers during the quarter, taking the installed base to nearly 11,000 instruments.
- Gross-margin expansion was supported by strong recurring-revenue volume gains, operational productivity initiatives, and net price realization.
- Veterinary software, services and diagnostic imaging systems revenue grew 11% reported and 10% organic, benefiting from diagnostic imaging systems installations led by ImageVue DR50 Plus.
Concerns
- Rapid assay products revenue increased 1% as reported and on an organic basis, as net price benefits offset lower testing volumes.
- CAG Diagnostics capital instrument revenue was flat on an as reported and organic basis.
- LPD revenue grew 3% as reported and organic.
- The company lowered its full-year reported operating-margin outlook to 32.1% - 32.3% from 32.3% - 32.5%, including acquisition-related impacts.
- Third-quarter EPS included $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and $0.04 per share benefit from year-over-year currency changes.
What to watch
- Delivery against full-year CAG Diagnostics recurring revenue growth guidance of 11.0% - 11.7% reported and 10.3% - 11.0% organic.
- The effect of the recent CoVet acquisition, which the updated revenue outlook includes at $5 million.
- Progress in operating-margin delivery against the 32.1% - 32.3% full-year outlook and 50 bps - 70 bps projected expansion.
- Sustainability of IDEXX VetLab consumables growth and premium instrument installed-base expansion.
- Testing-volume trends in rapid assay products and the pace of CAG Diagnostics capital instrument revenue.
- IDEXX's Investor and Analyst Session at VMX in Orlando, Florida on January 18th, which will highlight IDEXX MultiCue Dx.
Balance sheet and cash flow
- Cash and cash equivalents at September 30, 2026: $197,536 thousand; December 31, 2025: $180,070 thousand.
- Line of credit at September 30, 2026: $474,000 thousand; December 31, 2025: $398,000 thousand.
- Current portion of long-term debt at September 30, 2026: $74,998 thousand; long-term debt, net of current portion: $299,879 thousand.
- Net cash provided by operating activities for the three months ended September 30, 2026: $449,717 thousand; prior year: $402,340 thousand.
- Net cash provided by operating activities for the nine months ended September 30, 2026: $1,063,127 thousand; prior year: $826,045 thousand.
- Purchases of property and equipment for the nine months ended September 30, 2026: $85,560 thousand; prior year: $95,242 thousand.
- Acquisitions for the nine months ended September 30, 2026: $227,122 thousand; prior year: $13,350 thousand.
- Net cash used by investing activities for the nine months ended September 30, 2026: $307,140 thousand; prior year: $108,109 thousand.
- Net cash used by financing activities for the nine months ended September 30, 2026: $737,466 thousand; prior year: $809,262 thousand.
Analysis
IDEXX reported third-quarter revenue of $1,214,237 thousand, up 9.9%, and organic revenue growth of 10.0%. CAG, the largest segment, generated $1,115,968 thousand of revenue and grew 10.2%. CAG Diagnostics recurring revenue was $967,351 thousand, up 10.8% reported and 11.0% organic, led by VetLab consumables growth of 14.3% reported and reference laboratory diagnostic and consulting-services growth of 10.0%. International CAG revenue grew 13.4%, compared with 8.6% in the United States.
The recurring diagnostics franchise was supported by strong same-store volume growth, innovation benefits, net customer gains and premium instrument installed-base expansion. IDEXX placed over 1,900 IDEXX inVue Dx analyzers during the quarter, bringing its installed base to nearly 11,000 instruments. VetLab consumables benefited from net new customer growth, 11% expansion of the global premium instrument installed base, utilization expansion and net price gains. The weaker components were rapid assay products, which increased 0.6% reported amid lower testing volumes, and CAG Diagnostics capital instruments, which were flat.
Profitability expanded despite continued investment. Gross profit increased 12% to $764,298 thousand and gross margin rose to 62.9% from 61.8%, supported by recurring-revenue volume gains, productivity initiatives and net price realization. Operating expenses increased 10% to $361,950 thousand as IDEXX expanded commercial capabilities and advanced its innovation agenda while absorbing acquisition impacts and transaction-related costs. Operating income increased 13% to $402,348 thousand, and operating margin increased to 33.1% from 32.1%. Diluted EPS was $4.01, up 18%, while comparable diluted EPS was $3.96, up 22%.
Cash generation remained substantial. Net cash provided by operating activities was $449,717 thousand in the quarter and $1,063,127 thousand for the first nine months. Free cash flow was $420,787 thousand for the quarter and $977,567 thousand for the nine-month period. IDEXX used $804,698 thousand for open-market repurchases in the first nine months and spent $227,122 thousand on acquisitions. Cash and cash equivalents were $197,536 thousand at September 30, 2026, while the line of credit was $474,000 thousand and long-term debt, net of current portion, was $299,879 thousand.
Management raised full-year revenue guidance to $4,741 - $4,767 million and EPS guidance to $14.96 - $15.16. The higher revenue outlook reflects strong CAG Diagnostics recurring revenue performance and includes $5 million related to the recent CoVet acquisition. The company also raised organic revenue growth guidance to 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth guidance to 10.3% - 11.0%. At the same time, it reduced reported operating-margin guidance to 32.1% - 32.3% from 32.3% - 32.5%, with the updated outlook including acquisition-related impacts.
Management, verbatim
IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy.
Mike Erickson, President and Chief Executive Officer
Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently.
Mike Erickson, President and Chief Executive Officer
In software, we advanced our capabilities with the acquisition of CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization, creating more value for our customers and shareholders.
Mike Erickson, President and Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter values and sequential changes for reported financial metrics were not provided.
- A third-quarter effective tax rate was not provided.
- A cash dividend amount or dividend declaration was not provided.
- Full-year gross-margin guidance and operating-expense guidance were not provided.
- Management did not provide a driver for Other segment revenue growth or nine-month segment revenue performance.
- The previous outlook covered the full year 2026 only, so there is no quarterly guidance to compare with this third-quarter release.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.